EDIT (Editas Medicine) Momentum Rank : 2 (As of Dec. 13, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine Momentum Rank?

Editas Medicine has the Momentum Rank of 2.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Editas Medicine's Momentum Rank

For the Biotechnology subindustry, Editas Medicine's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Editas Medicine's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Momentum Rank falls into.

Editas Medicine Momentum Rank Related Terms

Thank you for viewing the detailed overview of Editas Medicine's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Editas Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (NAS:EDIT) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

0IFK:UK 8EM:Germany

Address

11 Hurley Street, Cambridge, MA, USA, 02141

Website

https://www.editasmedicine.com

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Executives

Baisong Mei	officer: SVP, CHIEF MEDICAL OFFICER	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Gilmore Neil O'neill	director, officer: CEO	215 FIRST STREET, CAMBRIDGE MA 02142
Linda Burkly	officer: EVP, CHIEF SCIENTIFIC OFFICER	1 MAIN STREET, CAMBRIDGE MA 02142
Erick Lucera	officer: EVP, CHIEF FINANCIAL OFFICER	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Jessica Hopfield	director	C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bruce Eaton	officer: EVP, Chief Business Officer	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michelle Robertson	officer: Chief Financial Officer	C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elliott M. Levy	director	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Mark S Shearman	officer: EVP, Chief Scientific Officer	C/O APPLIED GENETIC TECHNOLOGIES CORP, 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Lisa Anne Michaels	officer: EVP/Chief Medical Officer	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Bernadette Connaughton	director	C/O VISTERRA, INC., ONE KENDALL SQUARE, #B3301, CAMBRIDGE MA 02139
James C Mullen	director	940 WINTER STREET, PERKINELMER, INC LEGAL DEPARTMENT, WALTHAM MA 02451
Emma Reeve	director	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Cynthia Collins	director	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Meeta Chatterjee	director	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142